摘要
目的探讨重组人粒细胞集落刺激因子(rhG-CSF)对中国肿瘤患者化疗后骨髓抑制的预防作用,为临床合理用药提供参考。方法采用回顾性调查方法,筛选上周期化疗后出现3～4度骨髓抑制的肿瘤患者,以化疗后24～48h内预防性给予rhG-CSF的为A组;以化疗后未预防性给药,发生骨髓抑制后再给予rhG-CSF的为B组,采用组间对照法,比较2组化疗后骨髓抑制的发生情况。结果入组的145例次肿瘤患者,A组61例次,B组84例次,白细胞计数<4.0×109.L-1的发生率分别为26.23%和79.76%,中性粒细胞计数<2.0×109.L-1的发生率分别为19.67%和78.57%,2组间均具有统计学差异(P<0.05)。rhG-CSF对化疗后血红蛋白、血小板水平无影响。A组抗菌药物的使用率显著低于B组。结论上周期化疗后出现3～4度骨髓抑制的肿瘤患者,化疗后24～48h内预防性给予rhG-CSF,能有效控制肿瘤化疗后骨髓抑制的发生,降低感染的风险,值得推广。
Objective To determine the preventive effect of recombinant human granulocyte colony-stimulating factor（rhG-CSF） used for chemotherapy-induced myelosuppression in Chinese tumor patients to guide clinical rational drug use.Methods Tumor patients who appeared grade 3 to 4 myelosuppression after upper-period chemotherapy were chosen in the retrospective study.Group A was preventively treated with rhG-CSF between 24-48 h after the chemotherapy,and group B was treated with rhG-CSF after the myelosuppression.Myelosuppression induced by chemotherapy was compared between the 2 groups.Results A total of 145 tumor patients were enrolled,with 61 patients in group A,and 84 in group B.The rate of leukopenia was 26.23% and 79.76%,and the rate of neutropenia was 19.67% and 78.57% in group A and the group B respectively.There was significant difference between the 2 groups（P0.05）.RhG-CSF had no effect on the hemoglobin and platelet.The antibiotics use in group A was lower than that in group B.Conclusion Prophylactic use of rhG-CSF between 24-48 h after the chemotherapy can reduce the myelosuppression and infection in tumor patients with grade 3 to 4 myelosuppression after the upper-period chemotherapy.
出处
《中南药学》
CAS
2012年第3期229-232,共4页
Central South Pharmacy
关键词
重组人粒细胞集落刺激因子
回顾性调查
预防性用药
骨髓抑制
recombinant human granulocyte colony-stimulating factor
retrospective survey
prophylactic drug use
myelosuppression
